Shionogi Secures Complete Ownership of Global Rights to RADICAVA (edaravone)
Shionogi & Co., Ltd. has announced the successful completion of a major strategic transaction involving the full transfer of rights to RADICAVA (edaravone), marking a significant milestone in the company’s transformation into a global rare disease leader. The agreement includes the acquisition of all intellectual property rights, commercial rights, and associated assets in major markets from Tanabe Pharma Corporation, with additional regional transfers expected to follow in the near future.
This transaction represents more than a simple product acquisition. It is a comprehensive integration effort that includes not only the RADICAVA brand and its global commercial footprint, but also the transfer of experienced personnel, operational capabilities, and development platforms associated with the therapy. Together, these elements are expected to significantly strengthen Shionogi’s infrastructure and expertise in the rare disease space, positioning the company as a commercially capable and innovation-driven player in this specialized therapeutic area.
RADICAVA is a well-established therapy approved by the U.S. Food and Drug Administration and multiple regulatory authorities worldwide for the treatment of amyotrophic lateral sclerosis (ALS). ALS is a progressive and ultimately fatal neurodegenerative disorder that affects motor neurons, leading to muscle weakness, paralysis, and loss of respiratory function. Despite ongoing research, the disease currently has no cure, and available treatment options remain limited, making therapies like RADICAVA critically important for patients and clinicians.
Since its introduction, RADICAVA has been available in both intravenous and oral formulations, with the oral suspension version (RADICAVA ORS) offering increased convenience and accessibility for patients. To date, more than 22,000 individuals living with ALS in the United States have been treated with RADICAVA, reflecting its role as a key therapeutic option in managing this devastating condition. The drug works by reducing oxidative stress, a factor believed to contribute to neuronal damage in ALS, thereby helping to slow the progression of functional decline in some patients.
For Shionogi, the acquisition aligns closely with its long-term corporate strategy, particularly its “2030 Vision,” which emphasizes expanding into new growth areas, including rare diseases. By bringing RADICAVA fully under its control, the company gains not only a revenue-generating asset but also an established presence in the ALS treatment landscape. This move is expected to serve as a foundation for broader investments in rare disease research, development, and commercialization.
Dr. Isao Teshirogi, President and Chief Executive Officer of Shionogi, highlighted the strategic importance of the acquisition, emphasizing that it demonstrates tangible progress toward the company’s long-term goals. He noted that the deal reflects Shionogi’s commitment to delivering high-quality medicines that protect patient health and improve quality of life. Importantly, he underscored that the acquisition goes beyond the product itself, encompassing the responsibility of maintaining and strengthening relationships with the ALS community, including patients, caregivers, and healthcare providers.
This sense of responsibility is particularly significant in the context of rare diseases, where patient communities are often tightly connected and highly engaged with treatment providers and pharmaceutical companies. Ensuring continuity of care during the transition of product ownership is therefore a critical priority. Shionogi has indicated that it is committed to maintaining uninterrupted access to RADICAVA while also continuing to invest in innovation aimed at improving outcomes for individuals living with ALS.
The financial terms of the transaction further highlight its scale and strategic importance. Under the agreement originally announced in December 2025, Shionogi completed the acquisition through its U.S. subsidiary, Shionogi Inc., with a lump-sum payment of $2.5 billion. In addition to the upfront payment, the deal includes provisions for potential future royalty payments based on sales performance, subject to specified conditions.
From a financial perspective, the acquisition is expected to deliver immediate benefits. Shionogi anticipates that the transaction will be accretive in fiscal year 2026, contributing approximately $700 million in annual global revenue. This projected revenue stream provides a strong foundation for further investment in research and development, as well as the expansion of the company’s commercial capabilities in key markets.
Nathan McCutcheon, President and CEO of Shionogi Inc., emphasized the importance of RADICAVA as a treatment option for ALS patients and reiterated the company’s commitment to supporting the community’s current and future needs. He highlighted the value of integrating the experienced cross-functional team from Tanabe Pharma, noting that their expertise will enhance Shionogi’s ability to build a best-in-class rare disease franchise in the United States.
The addition of this team is expected to accelerate Shionogi’s efforts to establish a strong presence in the U.S. rare disease market, one of the most competitive and innovation-driven healthcare environments globally. By combining internal capabilities with the newly acquired expertise, the company aims to create a robust platform capable of supporting both the commercialization of existing therapies and the development of future treatments.
Beyond ALS, the acquisition signals Shionogi’s broader ambition to expand its footprint in rare diseases, an area characterized by high unmet medical need, specialized patient populations, and increasing scientific innovation. Rare disease therapies often require targeted approaches, deep engagement with patient communities, and close collaboration with regulatory authorities, all of which are areas where Shionogi is now seeking to build and strengthen its capabilities.
In addition, the transaction underscores a growing trend within the pharmaceutical industry toward strategic acquisitions that provide not only products but also integrated capabilities and expertise. By acquiring RADICAVA along with its associated infrastructure, Shionogi is effectively accelerating its entry into the rare disease space, reducing the time and investment required to build these capabilities from scratch.
Looking ahead, the successful integration of RADICAVA and its associated operations will be a key factor in determining the long-term success of this strategy. Shionogi’s ability to maintain strong relationships with the ALS community, ensure consistent product supply, and continue advancing innovation in ALS treatment will be closely watched by stakeholders across the healthcare ecosystem.
In conclusion, the completion of the RADICAVA rights transfer marks a transformative moment for Shionogi & Co., Ltd., reinforcing its commitment to rare diseases and positioning the company for sustained growth in this critical area of healthcare. With a proven therapy, an experienced team, and a clear strategic vision, Shionogi is now well positioned to make a meaningful impact on the lives of patients living with ALS while continuing to expand its role as a global leader in rare disease innovation.
About RADICAVA ORS ® (edaravone)
The U.S. Food and Drug Administration (FDA) approved RADICAVA ORS® (edaravone) on May 12, 2022, for the treatment of amyotrophic lateral sclerosis (ALS). In 2024, the FDA granted RADICAVA ORS Orphan Drug Exclusivity based on its major contribution to patient care by providing an oral suspension route of administration that avoids the burdens of IV administration. RADICAVA ORS is taken daily for 14 consecutive days followed by a 14-day drug-free period for the initial treatment cycle.
For subsequent treatment cycles, RADICAVA ORS is taken for 10 days within a 14-day period followed by a 14-day drug-free period. Each 105 mg (5mL) dose of RADICAVA ORS should be taken in the morning after overnight fasting. Patients should not eat or drink (except water) within one hour after taking RADICAVA ORS.1
Edaravone was discovered and developed for ALS by Tanabe Pharma and commercialized in the U.S. by Tanabe Pharma America, Inc. The Tanabe Pharma group companies began researching ALS in 2001 through an iterative clinical platform over a 13-year period. In 2015, edaravone was approved as RADICUT® for the treatment of ALS in Japan and South Korea. Marketing authorizations were subsequently granted in Canada (October 2018), Switzerland (January 2019), Indonesia (July 2020), Thailand (April 2021), Malaysia (December 2021), Australia (February 2023) and Brazil (February 2024).
Marketing authorization for RADICAVA® Oral Suspension was granted in Canada (November 2022) and Switzerland (May 2023), and RADICUT® Oral Suspension 2.1% was granted regulatory approval in Japan in December 2022. To date, in the U.S., RADICAVA ORS, along with the previously available IV RADICAVA® (edaravone), have been used to treat over 22,000 people with ALS, with over 2.8-million days of therapy, and have been prescribed by over 2,800 HCPs.2,3
Source Link:https://www.businesswire.com/
